Riboflavin and ultraviolet light treatment potentiates vasodilator- stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage

Transfusion

Volumn 52, Issue 2, 2012, Pages 397-408

  Schubert, Peter ^a   Culibrk, Brankica ^a   Coupland, Danielle ^a   Scammell, Ken ^a   Gyongyossy Issa, Maria ^a   Devine, Dana V ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PADGEM PROTEIN; RIBOFLAVIN; SERINE; THROMBOCYTE CONCENTRATE; VASODILATOR STIMULATED PHOSPHOPROTEIN;

APHERESIS; ARTICLE; AUTOMATION; BLOOD STORAGE; BLOOD TRANSFUSION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MEDICAL INSTRUMENTATION; MEDICAL TECHNOLOGY; PHOTOCHEMISTRY; PLASMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; ULTRAVIOLET RADIATION;

BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOOD PRESERVATION; CELL ADHESION MOLECULES; HUMANS; MATERIALS MANAGEMENT, HOSPITAL; MICROFILAMENT PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET COUNT; PLATELET TRANSFUSION; PROTEIN-SERINE-THREONINE KINASES; PROTEOMICS; QUALITY CONTROL; RIBOFLAVIN; SERINE; ULTRAVIOLET RAYS; UP-REGULATION;

EID: 84855859462     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03287.x     Document Type: Article

References (35)

1. Corbin F,. Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer. Int J Hematol 2002; 76 Suppl 2: 253-7.
2. Seghatchian J, de Sousa G,. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006; 35: 189-96. (Pubitemid 44839272)
3. Solheim BG, Seghatchian J,. The six questions of pathogen reduction technology: an overview of current opinions. Transfus Apher Sci 2008; 39: 51-7.
4. Kumar V, Lockerbie O, Keil SD, Ruane PH, Platz MS, Martin CB, Ravanat JL, Cadet J, Goodrich RP,. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80: 15-21.
5. Goodrich RP, Edrich RA, Li J, Seghatchian J,. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35: 5-17. (Pubitemid 44354317)
6. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP,. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-85. (Pubitemid 38738418)
7. Cardo LJ, Salata J, Mendez J, Reddy H, Goodrich R,. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007; 37: 131-7. (Pubitemid 350181574)
8. Tonnetti L, Proctor MC, Reddy HL, Goodrich RP, Leiby DA,. Evaluation of the Mirasol pathogen reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion 2010; 50: 1019-27.
9. Hervig T, Seghatchian J, Apelseth TO,. Current debate on pathogen inactivation of platelet concentrates-to use or not to use? Transfus Apher Sci 2010; 43: 411-4.
10. Picker SM, Steisel A, Gathof BS,. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008; 48: 1685-92.
11. Picker SM, Steisel A, Gathof BS,. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study. Transfus Apher Sci 2009; 40: 79-85.
12. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP,. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-41. (Pubitemid 41647801)
13. Cazenave JP, Folléa G, Bardiaux L, Boiron JM, Lafeuillade B, Debost M, Lioure B, Harousseau JL, Deconinck E, Tabrizi R, Cahn JY, Michallet M, Ambruso D, Tissot JD, Sensebé L, Kondo T, McCullough J, Rebulla P, Escolar G, Mintz P, Heddle NM, Goodrich RP, Bruhwyler J, Le C, Cook RJ, Stouch B, Fletcher D, Deberdt L,. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2011; 50: 2362-75.
14. Schubert P, Devine DV,. Proteomics meets blood banking: identification of protein targets for the improvement of platelet quality. J Proteomics 2010; 73: 436-44.
15. Thiele T, Steil L, Gebhard S, Scharf C, Hammer E, Brigulla M, Lubenow N, Clementson KJ, Volker U, Greinacher A,. Profiling of alterations in platelet proteins during storage of platelet concentrates. Transfusion 2007; 47: 1221-33. (Pubitemid 46934314)
16. Thon JN, Schubert P, Duguay M, Serrano K, Lin S, Kast J, Devine DV,. Comprehensive proteomic analysis of protein changes during platelet storage requires complementary proteomic approaches. Transfusion 2008; 48: 425-35. (Pubitemid 351294569)
17. Schubert P, Thon JN, Walsh GM, Chen CH, Moore ED, Devine DV,. A signaling pathway contributing to platelet storage lesion development: targeting PI3-kinase-dependent Rap1 activation slows storage-induced platelet deterioration. Transfusion 2009; 49: 1944-55.
18. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS,. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999; 20: 3551-67. (Pubitemid 30007252)
19. Dumont LJ, AuBuchon JP, Gulliksson H, Slichter SJ, Elfath MD, Holme S, Murphy JR, Rose LE, Popovsky MA, Murphy S,. In vitro pH effects on in vivo recovery and survival of platelets: an analysis by the BEST Collaborative. Transfusion 2006; 46: 1300-5. (Pubitemid 44117955)
20. Mohr H, Steil L, Gravemann U, Thiele T, Hammer E, Greinacher A, Muller TH, Volker U,. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009; 49: 2612-24.
21. Galan AM, Lozano M, Molina P, Navalon F, Maschner S, Goodrich RP, Escolar G,. Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function. Transfusion 2011; 51: 808-15.
22. Ostrowski SR, Bochsen L, Windelov NA, Salado-Jimena JA, Reynaerts I, Goodrich RP, Johansson PI,. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2011; 51: 344-56.
23. Reikvam H, Marschner S, Apelseth TO, Goodrich RP, Hervig T,. The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution. Blood Transfus 2010; 8: 186-92.
24. Li J, Lockerbie O, de Korte D, Rice J, McLean R, Goodrich RP,. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005; 45: 920-6. (Pubitemid 40798783)
25. Li J, de Korte D, Woolum MD, Ruane PH, Keil SD, Lockerbie O, McLean R, Goodrich RP,. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004; 87: 82-90. (Pubitemid 39265454)
26. Schrezenmeier H, Seifried E,. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 2011; 99: 1-15.
27. Vassallo RR, Murphy S,. A critical comparison of platelet preparation methods. Curr Opin Hematol 2006; 13: 323-30. (Pubitemid 44168452)
28. Albanyan AM, Harrison P, Murphy MF,. Markers of platelet activation and apoptosis during storage of apheresis- and buffy coat-derived platelet concentrates for 7 days. Transfusion 2009; 49: 108-17.
29. van Marwijk Kooy M, Akkerman JW, van Asbeck S, Borghuis L, van Prooijen HC,. UVB radiation exposes fibrinogen binding sites on platelets by activating protein kinase C via reactive oxygen species. Br J Haematol 1993; 83: 253-8. (Pubitemid 23060922)
30. Verhaar R, Dekkers DW, De Cuyper IM, Ginsberg MH, de Korte D, Verhoeven AJ,. UV-C irradiation disrupts platelet surface disulfide bonds and activates the platelet integrin alphaIIbbeta3. Blood 2008; 112: 4935-9.
31. Devine DV, Schubert P,. Proteomic applications in blood transfusion: working the jigsaw puzzle. Vox Sang 2011; 100: 84-91.
32. Liumbruno GM,. Proteomics: applications in transfusion medicine. Blood Transfus 2008; 6: 70-85. (Pubitemid 352025963)
33. Benz PM, Blume C, Seifert S, Wilhelm S, Waschke J, Schuh K, Gertler F, Munzel T, Renne T,. Differential VASP phosphorylation controls remodeling of the actin cytoskeleton. J Cell Sci 2009; 122: 3954-65.
34. Flaumenhaft R, Dilks JR, Rozenvayn N, Monahan-Earley RA, Feng D, Dvorak AM,. The actin cytoskeleton differentially regulates platelet alpha-granule and dense-granule secretion. Blood 2005; 105: 3879-87. (Pubitemid 40656132)
35. Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F, Barragan P, Camoin-Jau L,. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630-6. (Pubitemid 47091403)